Published in J Immunol on June 23, 2014
Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection. MBio (2015) 0.89
Influenza vaccines: a moving interdisciplinary field. Viruses (2014) 0.81
Single-Dose CpG Immunization Protects Against a Heterosubtypic Challenge and Generates Antigen-Specific Memory T Cells. Front Immunol (2015) 0.81
A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine. J Virol (2014) 0.81
Prospects of HA-based universal influenza vaccine. Biomed Res Int (2015) 0.79
Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage. J Gen Virol (2015) 0.78
Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever. PLoS Pathog (2016) 0.77
Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. Int J Nanomedicine (2016) 0.75
Monocyte-derived dendritic cells enhance protection against secondary influenza challenge by controlling the switch in CD8(+) T-cell immunodominance. Eur J Immunol (2016) 0.75
Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo. PLoS One (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Recognition of microorganisms and activation of the immune response. Nature (2007) 12.99
Type 1 interferons and the virus-host relationship: a lesson in détente . Science (2006) 6.33
Systems biology of vaccination for seasonal influenza in humans. Nat Immunol (2011) 6.09
Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature (2005) 5.32
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
A plasmid-based reverse genetics system for influenza A virus. J Virol (1996) 4.33
Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (2013) 4.18
Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science (2013) 4.14
Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells. J Exp Med (2008) 3.97
Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol (2004) 3.81
From vaccines to memory and back. Immunity (2010) 3.30
Influenza and the challenge for immunology. Nat Immunol (2006) 3.24
Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis (2005) 3.20
Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol (2009) 3.09
Influenza A viruses: new research developments. Nat Rev Microbiol (2011) 3.00
Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine (2005) 2.82
Origins of CD4(+) effector and central memory T cells. Nat Immunol (2011) 2.35
Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenza. Nat Immunol (2010) 2.27
Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol (1998) 2.03
Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med (2010) 1.90
Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect (2008) 1.88
The discovery of MHC restriction. Immunol Today (1997) 1.76
Analysis of clonotype distribution and persistence for an influenza virus-specific CD8+ T cell response. Immunity (2003) 1.74
Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol (2005) 1.67
TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J Immunol (2011) 1.61
Regulation of effector and memory T-cell functions by type I interferon. Immunology (2011) 1.58
Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. J Clin Invest (2012) 1.57
Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS One (2009) 1.44
Inflammatory chemokine receptors regulate CD8(+) T cell contraction and memory generation following infection. J Exp Med (2011) 1.40
Lung airway-surveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus. Immunity (2013) 1.33
Hidden epitopes emerge in secondary influenza virus-specific CD8+ T cell responses. J Immunol (2007) 1.28
Attenuation and immunogenicity in mice of temperature-sensitive influenza viruses expressing truncated NS1 proteins. J Gen Virol (2005) 1.11
Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. J Immunol (2010) 1.11
Antigen availability determines CD8⁺ T cell-dendritic cell interaction kinetics and memory fate decisions. Immunity (2013) 1.09
Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates. Blood (2009) 1.08
p53 serves as a host antiviral factor that enhances innate and adaptive immune responses to influenza A virus. J Immunol (2011) 1.08
Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine (2009) 1.05
TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help. Blood (2007) 1.04
Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses. J Virol (2009) 1.01
Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine (2011) 0.90
Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect (2006) 0.89
Pathogen replication, host inflammation, and disease in the upper respiratory tract. Infect Immun (2013) 0.84
Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge. Arch Virol (2012) 0.78